Jones Trading sets OnKure stock Buy rating, $32 target
Jones Trading initiated coverage on OnKure Therapeutics Inc. (NASDAQ:OKUR) with a Buy rating and a price target of $32.00.
OnKure Therapeutics initiated with a Buy at JonesResearch
JonesResearch initiated coverage of OnKure Therapeutics (OKUR) with a Buy rating and $32 price target. The clinical stage precision oncology ...
Positive Outlook for Relay Therapeutics: Buy Rating on Promising RLY-2680 Developments and Market Opportunities
JMP Securities analyst Silvan Tuerkcan maintained a Buy rating on Relay Therapeutics (RLAY – Research Report) today and set a price target of ...
Scorpion's RevenueMAX Wins BIG Innovation Award
Scorpion is thrilled to announce its recognition as a winner in the prestigious 2025 BIG Innovation Awards, presented by the ...
stockhead2d
Health Check: The urge to merge is spurring a global biotech recovery
Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.
Relay Therapeutics Inc (RLAY): AI-Driven Cancer Treatments Backed by Barclays’ $17 Price Target
Relay Therapeutics Inc. (NASDAQ:RLAY) is a leading clinical-stage precision medicines firm focused on cancer treatments. The ...